Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
LowReport
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia [Yahoo! Finance]
LowReport
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia [Yahoo! Finance]
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
LowReport
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $183.00 to $184.00. They now have an "overweight" rating on the stock.
LowReport
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $183.00 to $184.00. They now have an "overweight" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: